Salicin — Safety, Research, Risks & Legal Status

Not medical advice. Salicin is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	D-Salicin, Salicoside, Salicine, Saligenin-β-D-glucopyranoside
Category	Supplement
Chemical class	Phenolic glycoside; salicylate derivative
Molecular formula	C13H18O7 (MW 286.28 g/mol; CAS 138-52-3)
Primary natural source	White willow bark (Salix alba and related Salix species)
Regulatory status (US)	Dietary supplement ingredient (DSHEA); USP monograph; no FDA drug approval
Key preclinical target identified	IRE1alpha (inositol-requiring enzyme 1-alpha); ER stress pathway suppression
Clinical evidence basis	Small RCTs (largest ~78 patients, 2-week duration) in osteoarthritis and musculoskeletal pain using standardized willow bark extract
US legal status	Not FDA-approved as a pharmaceutical drug. Regulated in the United States as a dietary supplement ingredient under DSHEA (Dietary Supplement Health and Education Act). A USP monograph exists. No known active NDA or IND filing for purified salicin as a standalone drug. Commercially available in standardized willow bark extract supplements.

What is Salicin?

Salicin is a naturally occurring phenolic glycoside (2-(hydroxymethyl)phenyl β-D-glucopyranoside, CAS 138-52-3) extracted primarily from the bark of white willow (Salix species) and related plants. It belongs to the salicylate family and has been used in traditional botanical medicine for over 2,000 years as a precursor to salicylate-based analgesia. Commercially it appears almost exclusively as a standardized willow bark extract, not as a purified pharmaceutical compound.

How it works

Salicin's pharmacological activity is multifactorial. After oral ingestion, it is hydrolyzed in the GI tract to salicyl alcohol, which is then oxidized to salicylic acid - a known anti-inflammatory salicylate. However, the concentration of salicin in typical willow bark doses is insufficient to account for observed analgesic effects through salicylate production alone. Preclinical research (PubMed: 36357568) has identified a second mechanism: salicin binds directly to IRE1alpha (inositol-requiring enzyme 1-alpha), suppressing IRE1alpha phosphorylation and attenuating endoplasmic reticulum (ER) stress signaling via the IRE1alpha-IkappaBalpha-p65 pathway, with downstream inhibition of pro-inflammatory cytokines including TNF-alpha, IL-1, and IL-6. The flavonoids and polyphenols co-occurring in whole willow bark extracts are believed to contribute meaningfully to the observed anti-inflammatory activity, making the whole-extract matrix pharmacologically distinct from isolated salicin. Whether isolated salicin recapitulates the full activity of willow bark extracts remains an open question in the literature.

Background & history

Willow bark has been used medicinally since antiquity, with documented references in ancient Egyptian, Greek, and Roman texts. The active glycoside salicin was first isolated from willow bark by Henri Leroux in 1828, and its chemical structure was characterized in subsequent decades. Salicin's metabolism to salicylic acid informed the synthesis of acetylsalicylic acid (aspirin) by Bayer in 1897. Interest in salicin as a distinct pharmaceutical entity - rather than simply a prodrug precursor to aspirin - has grown as its independent IRE1alpha-binding mechanism has been characterized in preclinical studies from approximately 2015 onward.

What the research says

Human clinical evidence for salicin, in the context of standardized willow bark extracts, is limited but exists. A randomized controlled trial (approximately 78 patients, 240 mg salicin/day, 2-week duration) demonstrated moderate analgesic efficacy in osteoarthritis. Published systematic reviews conclude that willow bark extracts show effectiveness for musculoskeletal pain, though the body of confirmatory trial data is mixed and the trials are generally small and short in duration (up to 6 weeks reported). Mechanistic work identifying IRE1alpha binding is preclinical (animal/cell studies; PubMed: 36357568). Rheumatoid arthritis pathway modulation via Nrf2-HO-1-ROS has also been described in preclinical models (PubMed: 29852739). No large Phase III trials of purified isolated salicin as a drug are apparent in the literature. The NCT03089697 and NCT03446053 trials listed under "N-Rephasin SAL200" are for a bacteriophage-derived endolysin product - that nomenclature is unrelated to the botanical salicin compound and should not be conflated.

Reported effects

Moderate analgesic effect in osteoarthritis and musculoskeletal pain, demonstrated in small RCTs of standardized willow bark extract (240 mg salicin/day)
Anti-inflammatory activity via inhibition of TNF-alpha, IL-1, and IL-6 (preclinical and proposed clinical mechanism)
Suppression of IRE1alpha-mediated ER stress signaling (preclinical; cell and animal models)
Metabolic conversion to salicylic acid in vivo, contributing to COX-inhibitory salicylate effects
Milder GI tolerability profile compared to aspirin, attributed to absence of direct acetylation of gastric mucosa
Potential modulation of Nrf2-HO-1-ROS pathways in inflammatory arthritis models (preclinical only)

Dosing & administration (informational)

Published clinical trials of standardized willow bark extract have used doses delivering 120-240 mg salicin per day as the standardized metric. These figures are drawn from the literature and are provided for informational context only - they do not constitute a dosing protocol or recommendation. Individual pharmacokinetics, comorbidities, concurrent medications (particularly anticoagulants and NSAIDs), and allergy history all affect appropriateness. Consult a licensed clinician before use.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

GI adverse effects (dyspepsia, nausea, epigastric discomfort) occur at lower rates than aspirin but are documented in sensitive individuals
Rare allergic reactions reported, including exanthema, pruritus, and facial edema; cases resolved within approximately 2 days of cessation
Cross-reactivity with aspirin is possible; contraindicated in patients with known aspirin or salicylate allergy
Does not significantly impair blood coagulation at doses of 240 mg salicin/day in available trials, in contrast to aspirin
Salicylate-sensitive individuals may react, though typical supplemental doses of willow bark salicin are lower than free salicylate loads from certain foods
Long-term safety data beyond 6 weeks are not well established in controlled trials
Drug interaction potential with anticoagulants, NSAIDs, and methotrexate should be considered, consistent with class effects of salicylates

Drug & supplement interactions

P
o
t
e
n
t
i
a
l
i
n
t
e
r
a
c
t
i
o
n
s
c
o
n
s
i
s
t
e
n
t
w
i
t
h
s
a
l
i
c
y
l
a
t
e
c
l
a
s
s
p
h
a
r
m
a
c
o
l
o
g
y
i
n
c
l
u
d
e
:
a
d
d
i
t
i
v
e
b
l
e
e
d
i
n
g
r
i
s
k
w
i
t
h
a
n
t
i
c
o
a
g
u
l
a
n
t
s
(
w
a
r
f
a
r
i
n
,
h
e
p
a
r
i
n
)
a
n
d
a
n
t
i
p
l
a
t
e
l
e
t
a
g
e
n
t
s
;
a
d
d
i
t
i
v
e
G
I
t
o
x
i
c
i
t
y
w
i
t
h
N
S
A
I
D
s
;
p
o
s
s
i
b
l
e
i
n
t
e
r
a
c
t
i
o
n
w
i
t
h
m
e
t
h
o
t
r
e
x
a
t
e
v
i
a
r
e
n
a
l
s
a
l
i
c
y
l
a
t
e
c
o
m
p
e
t
i
t
i
o
n
;
c
a
u
t
i
o
n
i
n
p
a
t
i
e
n
t
s
t
a
k
i
n
g
c
o
r
t
i
c
o
s
t
e
r
o
i
d
s
.
C
r
o
s
s
-
r
e
a
c
t
i
v
i
t
y
w
i
t
h
a
s
p
i
r
i
n
i
s
t
h
e
p
r
i
m
a
r
y
d
o
c
u
m
e
n
t
e
d
a
l
l
e
r
g
y
-
b
a
s
e
d
i
n
t
e
r
a
c
t
i
o
n
.
E
v
i
d
e
n
c
e
s
p
e
c
i
f
i
c
t
o
i
s
o
l
a
t
e
d
s
a
l
i
c
i
n
r
a
t
h
e
r
t
h
a
n
w
h
o
l
e
w
i
l
l
o
w
b
a
r
k
e
x
t
r
a
c
t
i
s
l
i
m
i
t
e
d
;
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
a
r
e
l
a
r
g
e
l
y
e
x
t
r
a
p
o
l
a
t
e
d
f
r
o
m
t
h
e
s
a
l
i
c
y
l
a
t
e
c
l
a
s
s
.

Who should avoid it

Patients with aspirin or NSAID allergy (cross-reactivity risk)
Patients on anticoagulant therapy without medical supervision
Patients with active peptic ulcer disease or significant GI pathology
Children and adolescents (salicylate compounds carry theoretical Reye syndrome risk in this population)
Patients with known salicylate sensitivity
Concurrent use with other NSAIDs without clinician oversight

How it is commonly combined

No well-characterized pharmaceutical stacking protocols exist for isolated salicin. In the context of whole willow bark extracts, the co-occurring flavonoids and polyphenols are believed to act synergistically with salicin - this is a property of the whole-plant matrix, not a designed stack. Combining with other salicylate-class compounds or NSAIDs increases GI and bleeding risk without established additive benefit.

Legal & regulatory. Not FDA-approved as a pharmaceutical drug. Regulated in the United States as a dietary supplement ingredient under DSHEA (Dietary Supplement Health and Education Act). A USP monograph exists. No known active NDA or IND filing for purified salicin as a standalone drug. Commercially available in standardized willow bark extract supplements.

Quality & harm reduction

S
a
l
i
c
i
n
i
s
c
o
m
m
e
r
c
i
a
l
l
y
a
v
a
i
l
a
b
l
e
i
n
s
t
a
n
d
a
r
d
i
z
e
d
w
i
l
l
o
w
b
a
r
k
e
x
t
r
a
c
t
s
f
r
o
m
m
u
l
t
i
p
l
e
n
u
t
r
a
c
e
u
t
i
c
a
l
m
a
n
u
f
a
c
t
u
r
e
r
s
,
w
i
t
h
s
t
a
n
d
a
r
d
i
z
a
t
i
o
n
t
y
p
i
c
a
l
l
y
e
x
p
r
e
s
s
e
d
a
s
m
g
s
a
l
i
c
i
n
p
e
r
d
o
s
e
.
I
t
i
s
a
l
s
o
a
v
a
i
l
a
b
l
e
a
s
a
r
e
s
e
a
r
c
h
-
g
r
a
d
e
p
u
r
e
c
o
m
p
o
u
n
d
f
r
o
m
c
h
e
m
i
c
a
l
s
u
p
p
l
i
e
r
s
(
e
.
g
.
,
S
i
g
m
a
-
A
l
d
r
i
c
h
c
a
t
a
l
o
g
S
0
6
2
5
)
.
A
s
a
d
i
e
t
a
r
y
s
u
p
p
l
e
m
e
n
t
i
n
g
r
e
d
i
e
n
t
,
i
t
i
s
s
u
b
j
e
c
t
t
o
U
S
P
m
o
n
o
g
r
a
p
h
s
t
a
n
d
a
r
d
s
,
t
h
o
u
g
h
t
h
i
r
d
-
p
a
r
t
y
t
e
s
t
i
n
g
p
r
a
c
t
i
c
e
s
v
a
r
y
b
y
m
a
n
u
f
a
c
t
u
r
e
r
.
C
o
n
s
u
m
e
r
s
s
h
o
u
l
d
s
e
e
k
p
r
o
d
u
c
t
s
w
i
t
h
d
o
c
u
m
e
n
t
e
d
t
h
i
r
d
-
p
a
r
t
y
c
e
r
t
i
f
i
c
a
t
e
o
f
a
n
a
l
y
s
i
s
.
B
a
t
c
h
-
t
o
-
b
a
t
c
h
v
a
r
i
a
b
i
l
i
t
y
i
n
w
h
o
l
e
-
p
l
a
n
t
e
x
t
r
a
c
t
s
i
s
a
k
n
o
w
n
l
i
m
i
t
a
t
i
o
n
.

Safer, legal alternative we recommend

Plat-Turmeric. For a legal anti-inflammatory support option, our Platinum Turmeric covers a similar goal.

See our recommended pick

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Is salicin the same as aspirin?

No. Salicin is a glycoside that is metabolically converted to salicylic acid in vivo; aspirin (acetylsalicylic acid) is a synthetic acetylated derivative of salicylic acid. Aspirin irreversibly inhibits COX-1 and COX-2 via acetylation, whereas salicin's primary mechanisms include the IRE1alpha-ER stress pathway and indirect salicylate production. The GI tolerability profile of salicin-containing willow bark extracts is generally better than aspirin in available comparisons, though cross-reactivity in aspirin-allergic patients remains a risk.

What does the human clinical evidence actually show?

The strongest available human evidence consists of small, short-duration RCTs (the largest involving approximately 78 patients over 2 weeks) using standardized willow bark extracts delivering 120-240 mg salicin per day. These suggest moderate analgesic benefit in osteoarthritis and musculoskeletal pain. Systematic reviews describe the evidence as suggestive but mixed, with trials generally underpowered by current standards. No large Phase III trials of purified isolated salicin as a pharmaceutical have been completed.

What is the IRE1alpha mechanism and why does it matter?

A 2022 preclinical study (PubMed: 36357568) identified that salicin binds directly to IRE1alpha, an enzyme central to the unfolded protein response and ER stress signaling. By blocking IRE1alpha phosphorylation and downstream IkappaBalpha-p65 (NF-kappaB) signaling, salicin suppressed pro-inflammatory cytokine production in osteoarthritis models. This is a distinct mechanism from COX inhibition and may explain why salicin's effects exceed what salicylate conversion alone would predict. This finding is currently preclinical (animal and cell studies) and has not been validated in human trials.

What is the recommended dose of salicin?

Published clinical trials have used doses standardized to 120-240 mg salicin per day from willow bark extracts. These figures are reported here as literature context only and do not constitute a dosing recommendation or protocol. Appropriate dose depends on individual health status, concurrent medications, and allergy history. A licensed clinician should be consulted before use.

Can salicin be used if someone is allergic to aspirin?

No. Cross-reactivity between salicin-containing willow bark extracts and aspirin has been documented and is a contraindication. Patients with known aspirin or NSAID sensitivity should avoid salicin-containing products. Rare but documented allergic reactions to willow bark extracts include skin rash, itching, and facial swelling.

Is salicin safe for children?

This is not established, and caution is warranted. Salicylate-class compounds carry a theoretical risk of Reye syndrome in children and adolescents, particularly in the context of viral illness. No clinical safety data for salicin in pediatric populations are available from the research notes reviewed. Use in children should not occur without explicit medical oversight.

References & further reading

PubMed: salicin IRE1alpha endoplasmic reticulum stress osteoarthritis IkappaBalpha p65 (PMID 36357568)
PubMed: willow species aspirin mechanism of action salicylate comparison (PMID 21226125)
PubMed: salicin Alangium chinense rheumatoid arthritis Nrf2 HO-1 ROS (PMID 29852739)
PubMed: systematic review willow bark musculoskeletal pain effectiveness (PMID 19140170)
ClinicalTrials.gov: willow bark extract osteoarthritis analgesic randomized controlled trial